{
  "ticker": "TRU",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02958527",
  "id": "02958527",
  "pages": 4,
  "price_sensitive": false,
  "date": "20250616",
  "time": "0834",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250616/pdf/06krwlcpd037fv.pdf",
  "summary": "### Key Market Update Summary:  \n\n- **Regulatory Approval in Uzbekistan**: Received approval to commence validation in Tashkent, precursor to a major public screening program.  \n- **Zimbabwe Validation**: Re-validation to be completed by **21 July 2025**, enabling program expansion to Harare and other provinces.  \n- **Vietnam Program Launch**: Screening of 260,000 women in Ho Chi Minh City to begin **28 July 2025**; staff training and device shipments completed.  \n- **First Commercial Order in India**: Purchase of **10 devices + 1,080 sensors** by Renovate Biologicals.  \n- **Clinical Study Validation**: Peer-reviewed study confirms TruScreen\u2019s **superior sensitivity (86.4%) and specificity (74.4%)** vs. traditional methods (TCT/HPV tests).  \n\n*No material financial or capital structure impacts disclosed.*",
  "usage": {
    "prompt_tokens": 2580,
    "completion_tokens": 184,
    "total_tokens": 2764,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-15T22:53:19.323829"
}